We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

186,000

200M

Downloads

154
Countries delivered to

Our authors are among the

 $\mathsf{TOP}\:1\%$

12.2%

most cited scientists

Contributors from top 500 universitie



WEB OF SCIENCE

Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us? Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected. For more information visit www.intechopen.com



Preemptive Kidney Transplantation

Burak Sayin Baskent University Faculty of Medicin, Ankara Turkey

1. Introduction

End-stage renal disease (ESRD) is a severe health problem with high mortality and morbidity rates and growing incidence worldwide. Recently, two main renal replacement therapy modalities have been used for ESRD patients: Dialysis and kidney transplantation. It is undoubtedly clear that transplantation is the best choise for long term survival and every transplantation candidate is also a preemptive transplantation candidate.

Preemptive kidney transplantation(PKT) may be summarized as transplantation before the commencement of dialysis in ESRD patients. Preemptive transplantation confers a significant benefit in terms of both patient and allograft survival. The benefit thought to be the result of avoidence of cardiovascular adverse effects of long term dialysis. Current opinion allows ESRD patients to receive PKT when their GFR is 20 mL per minute or less and preparation for transplantation should be started at the time of the diagnosing chronic renal disease.

Kidney transplantation should be the choise of therapy in ESRD patients not only because of improving graft and patient survival and also preventing dialysis related comorbidities and lower cost in the long term(1,2,3). New and more effective immunsupressive drugs, growing experience in transplantation surgery are making kidney transplantation a more common and safe option.

Although there are studies showing nephrologists have the same opinion that preemptive transplantation is the best treatment modality for eligible ESRD patients, that has been convincingly shown to improve posttransplant graft and patient survival. Unfortunately, while PKT is much more beneficial over transplantation, preemptive kidney transplantation seems to be underutilized specially as a result of late referral of the patients to a nephrologist and transplantation center. Only 2% of ESRD patients receive PKT while one forth of transplantation procedures are preemptive in children in the USA. Of course, there are other difficulties for PKT such as poor health status, lack of compliance, comorbidities, older patients, longer waiting time for deceased kidney donors and lack of social insurance. Ideally, preparation for transplantation should be initiated as soon as progressive chronic kidney disease (CKD) is recognized because cardiovascular morbidity and mortality rates increases while CKD progresses. Early referral to a nephrologist has a vital importance in this situation. Unfortunately, just about 50% of CKD patients come upon a nephrologist in end stage of chronic renal disease. Early referral not only allows careful preparation for PKT and also evaluation of potential living donor candidates and selecting the exact time for transplantation. Because the course of CKD varies according to the primary disease, earliest referral is synonymous to early preparation and beter outcome for transplantation.

GFR 20 mL per minute or less is widely accepted to be the time for preemptive kidney transplantation regardless of the etiology of the kidney disease. Diabetic CKD patients should also be evaluated for pancreatic islet cell transplantation. Kidney biopsy may be helpful for potentially recurring primary kidney diseases after transplantation. A living kidney donor enhances the chance for PKT but deceased kidney donor may be an alternative that should not be failed to remember and all patients should be added to waiting list when GFR decreases under 20 mL per minute. Previously transplantated patients may also be candidates for another PKT.

Recent studies show that preemptive transplantation has better outcomes than non-preemptive transplantation. Lower infection, lower hypertension and less acute rejection episode rates in preemptive transplant patients may be the main reasons for these results. PKT allows preventing from complications during hemodialysis, higher hemoglobin levels before transplantation, lower cardiovascular disease and coronary artery calcification rates, better consistency to immunsuppressive therapy and beter life-quality. Long term graft and patient survival are two major motivators for PKT.

Although kidney transplantation has many advantages against other therapeutic approaches, has its own problems. While kidney transplantation becomes more prevalent, post transplant problems growing as well and transplant recipients becomes a "special patient group". Minimazing the problems of this "special patient group" is a significant target and may only be achieved by proper choise of recipients, appropriate preparation and finally exact timing of transplantation.

Is preemptive kidney transplantation exact time of transplantation? Until mid 80's preemptive transplantation has been thought to have worse results than non preemptive (4,5). But after 90's more recent studies referred just the opposite (6,7). Currently, the question stil remains controversial for nephrologists.

Both in Turkey and in the world, widening of transplantation centers and experienced surgeons and nephrologists PKT has become a more common option. Specially in stage 3 and stage 4 CKD patients early referral to a transplantation center carries a high importance for long term survival.

In USA, PKT constitude 25% of living donor transplantations and 10% of deceased donor transplantations, while the rates are 34% and 14% for chidren recipients respectively(8,9). PKT in children has beter percentages because of family relationships, easier to find a donor for children and probably more doubt of adult nephrologist for PKT (10).

PKT offers preventing dialysis related co-morbidities. Approximately 20% of hemodialysis patients have been hospitalized for vascular access problems and 50% has cateter infections per year. In addition prolonging of hemodialysis process results irreversible cardiovascular problem even after transplantation (7,11). PKT has beter outcomes for both post transplant graft and patient survival and also co-morbidities happening during a dialysis period (10,11).

Mange et al showed improved graft survival of PKT in 8481 living donor transplantation with 52% decrease for graft loss for PKT over non preemptive (12). Kasiske et al found similar results for both living and deceased donor transplantation(13). Chronic allograft nephropathy rates are lower for PKT (14). Some investigators suggest that improved graft survival in PKT patients is a natural result of beter patient survival of selected patients for PKT. Besides other factors for graft survival are similar (15).

It is clear that prolongation of dialysis period in non-preemptive transplantation may result irreversible complications such as cardiovascular disease, renal allograft vascular disease,

malnutrition, chronic inlammation, impaired immunologic functions and inadequate clearence in ESRD patients (16,17). Immun system impairment may cause unavoidable infections during dialysis period (18,19,20). Non-preemptive transplantation patients expose to dialysis membranes that may cause activations in immun system which may even cause acute rejection (21,22,23). Hypertensionand left ventricular hypertrophy are more common in nonpreemptive group because of the interdialytic weight gain.

Kidney transplantation should be the first choise in ESRD patients. PKT may be termed as *créme de la créme* and should never be underestimated. Preparation for transplantation should be initiated at the time CKD has been diagnosed and every CKD patient should be accepted as a candidate for PKT for better survival and life-quality.

2. Results and offers

Every CRD patient is a candidate for PKT.

PKT is an important alternative to avoid from dialysis related co-morbidities and complications.

PKT has improved graft and patient survival rates over non preemptive KT.

Early referral to a transplantation center allows proper choise of recipients, appropriate preparation and finally exact timing of transplantation.


PKT offers lower infection rates, lower cardiovascular disease and better life quality.

Every transplantation candidate is also a preemptive transplantation candidate.

3. References

- [1] Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable renal transplant outcomes: a paired donor kidney analysis. Transplantation 74: 1377–1381, 2002.
- [2] Wolfe RA, Ashby VB, Milford EL. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipientss of a first cadaveric transplant. N Engl J Med 341: 1725, 1999.
- [3] Evans R. Cost effectiveness analysis of transplantation. Sug Clin North Am 66: 603-608, 1986.
- [4] Jacobs C, Brunner FP, Chantler C. Combined report on regular dialysis and transplantation in Europe. Proc Eur Dial Transplant Assoc 14: 3-9, 1977.
- [5] Kramer P, Broyer M, Brunner FP. Combined report of regular dialysis in Europe. Proc Dial Transplant Assoc 19: 4-8, 1981.
- [6] Migliori RJ, Simmons RL, Payne WD. Renal transplantation done safely without prior chronic dialysis therapy. Transplantation 43: 51-56, 1987.
- [7] Katz SM, Kerman RH, Golden D. Preemptive transplantation. An analysis of benefits and hazards in 85 patients. Transplantation 51: 351-355, 1991.
- [8] John AG, Rao M, Jacob CK. Pre-emptive live-related renal transplantation. Transplantation 66:204-209, 1998.
- [9] Papalois VE, Moss A, Gillingham KJ. Preemptive transplant for patients with renal failure. Arguments against waiting until dialysis. Transplantation 70(4): 625-631, 2000.

- [10] Mange K, Joffe MM, Feldman HI. Effect of the use or nonuse of long term dialysis on the subsequent survival of renal transplants on living donors. N Eng J Med 8: 726-731, 2001.
- [11] Vats A, Donaldson L, Fine R. Pretransplant dialysis status and outcome of renal transplantation in north american children: a NAPRTCS study. Transplantation 69: 1414-1419, 2000.
- [12] Mange K, Weir M. Preemptive renal transplantation: Why not? Am J Transplant 3: 1336-1340, 2003.
- [13] Wali RKGW, Bellimokunda L, Blahut S. What happens to patients with CHF due to left ventricular sistolic dysfunction defined as left ventricular ejection fraction (LVEF) of less than 40% (congestive cardiomyopathy in uremia) in dialysis dependent patients after successful renal transplantation? Am J Transplant 3(S5): 313, 2003.
- [14] Kasiske BL, SJ.Matas AJ, Ellison MD. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol 13: 1358-1364, 2002.
- [15] Innocenti GR, Wadei HM, Prieto M. Preemptive living donor kidney transplantation: Do benefits extend to all recipients? Transplantation 83: 144-149, 2007.
- [16] Gill JS, Tonello M, Johnson N. Why do preemptive kidney transplant recipients have an allograft survival advantage? Transplantation 78: 873-879, 2004.
- [17] Wolfe RA, Ashby VB, Daugirdas JT. Body size, dose of hemodialysis, and mortality. Am J Kidney Dis 35: 80-88, 2000.
- [18] Drukker A, Schlesinger M. The Immune system in uremia. Child Nephrol Urol 10: 61-64, 1990.
- [19] Meier-Kriesche HU, Port FK, Ojo A. Effect of waiting time on renal transplant outcome. Kidney Int 58: 1311-1317, 2000.
- [20] Nishimoto A, Matsumoto Y. Increase of periferal natural killer T cells in hemodialysis patients. Clin Nephrol 55: 121, 2001.
- [21] Kaul H, Girndt M, Sester U. Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end stage renal disease. Am J Kidney Dis 35: 611, 2000.
- [22] Cooper AC, Mikhail A, Lethbridge MW. Increased expression of erytropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, IL-13) by T cells in patients excibiting poor responce to erytropoietin therapy. J Am Soc Nephrol 14: 1776, 2003.
- [23] Joo KW, Shin SJ, Lee JW. Preemptive transplantation and long term outcome in living donor kidney transplantation, single center experience. Trans Proceed 39: 3061-3064, 2007.



Understanding the Complexities of Kidney Transplantation

Edited by Prof. Jorge Ortiz

ISBN 978-953-307-819-9
Hard cover, 564 pages
Publisher InTech
Published online 06, September, 2011
Published in print edition September, 2011

Kidney transplantation is a complex field that incorporates several different specialties to manage the transplant patient. This book was created because of the importance of kidney transplantation. This volume focuses on the complexities of the transplant patient. In particular, there is a focus on the comorbidities and special considerations for a transplant patient and how they affect kidney transplant outcomes. Contributors to this book are from all over the world and are experts in their individual fields. They were all individually approached to add a chapter to this book and with their efforts this book was formed. Understanding the Complexities of Kidney Transplantation gives the reader an excellent foundation to build upon to truly understand kidney transplantation.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Burak Sayin (2011). Preemptive Kidney Transplantation, Understanding the Complexities of Kidney Transplantation, Prof. Jorge Ortiz (Ed.), ISBN: 978-953-307-819-9, InTech, Available from: http://www.intechopen.com/books/understanding-the-complexities-of-kidney-transplantation/preemptive-kidney-transplantation



InTech Europe

University Campus STeP Ri Slavka Krautzeka 83/A 51000 Rijeka, Croatia Phone: +385 (51) 770 447

Fax: +385 (51) 686 166 www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai No.65, Yan An Road (West), Shanghai, 200040, China 中国上海市延安西路65号上海国际贵都大饭店办公楼405单元

Phone: +86-21-62489820 Fax: +86-21-62489821 © 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the <u>Creative Commons Attribution-NonCommercial-ShareAlike-3.0 License</u>, which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited and derivative works building on this content are distributed under the same license.



